Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Heart and Blood Diseases

Rare Diseases

Recurrence

Lymphoma

Leukemia

Leukemia, Lymphoid

Leukemia, Lymphocytic, Chronic, B-Cell

Lymphoma, Mantle-Cell

Lymphoma, Large B-Cell, Diffuse

Lymphoma, B-Cell

Waldenstrom Macroglobulinemia

Leukemia, Hairy Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Hematologic Diseases

Disease Attributes

Lymphoma, Non-Hodgkin

Leukemia, B-Cell

Chronic Disease

Neoplasms, Plasma Cell

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hemorrhagic Disorders

Lymphosarcoma

Chronic Graft Versus Host Disease

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Hairy Cell Leukemia

Dendritic Cell Tumor

Blastic Plasmacytoid Dendritic Cell

Patients previously treated with MB-102 CAR-T cell investigational product.

Patients previously treated with MB-106 CAR-T cell investigational product.

No investigational product will be administered.

Prior MB-102 CAR-T cell investigational product.

Prior MB-106 CAR-T cell investigational product.

Bruce Dezube, M.D.

A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.

Non-interventional, multi-center, long-term follow-up study of subjects previously treated with a Mustang Bio CAR-T cell investigational product in a Mustang Bio sponsored clinical study. Subjects who enroll will be monitored for a total of up to 15 years from the time of their last investigational product infusion.

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

A Long-term Follow-up Study in Patients Previously Treated With Mustang Bio, Inc. CAR-T Cell Investigational Products

Incidence and characterization of adverse events (AEs) related to prior treatment with a Mustang Bio CAR-T cell investigational product received in a Mustang Bio sponsored clinical study.

Detection of replication competent lentivirus (RCL).

Mustang Bio

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Anti-Inflammatory Agents

Antiemetics

Gastrointestinal Agents

Cytarabine

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Doxorubicin

Liposomal doxorubicin

Dexamethasone

Prednisone

Rituximab

Vincristine

Dexamethasone acetate

Sirolimus

Temsirolimus

MTOR Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Immunosuppressive Agents

Immunologic Factors

Anti-Bacterial Agents

Antibiotics, Antitubercular

Clotrimazole

Miconazole

Antifungal Agents

Antineoplastic Agents, Alkylating

Alkylating Agents

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Tubulin Modulators

Antimitotic Agents

Antineoplastic Agents, Immunological

Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 15 mg

Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 25 mg

Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 50 mg

Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 75 mg

Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Torisel dose 15 mg and R-CHOP

Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Torisel dose 15 mg and R-FC

Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Torisel dose 15 mg and R-DHA

Torisel dose 25 mg and R-CHOP

Torisel dose 50 mg and R-CHOP

Torisel dose 75 mg and R-CHOP

Torisel dose 25 mg and R-FC

Torisel dose 50 mg and R-FC

Torisel dose 75 mg and R-FC

Torisel dose 25 mg and R-DHA

Torisel dose 50 mg and R-DHA

Torisel 75 mg and R-DHA

Steven LE GOUILL, Professor

This is a multicenter, open label, three arms, Phase IB study.

A dose escalation phase of Temsirolimus (Torisel™) administered in intravenous (IV) at day 2, day 8 and day 15 in combination with three chemotherapies regimens for patients in relapsed/refractory Mantle Cell Lymphoma (MCL):

* Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks for 6 cycles,
* Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks for 6 cycles,
* Rituximab-Aracytine high dose-Dexamethasone (R-DHA) administered every 4 weeks for 6 cycles.

This is a three arms trial that investigates Temsirolimus (Torisel™) in combination with three chemotherapy regimens (R-CHOP, R-FC or R-DHA).

Primary Objective:

- To assess the feasibility of these three chemotherapy regimens in combination with Temsirolimus (Torisel™) and to assess the incidence of dose limiting toxicities (DLT) during the two first cycles of Temsirolimus (Torisel™) in combination with three chemotherapy regimens in order to determine the maximal tolerate dose (MTD) in a dose escalating study design in a population of patients in relapsed/refractory Mantle Cell Lymphoma (MCL).

Secondary objectives:

* To assess the safety of the association Temsirolimus with the three chemotherapy regimens,
* To determine the efficacy of the association of Temsirolimus (Torisel™) and these three chemotherapy regimens after 4 cycles and after 6 cycles at the end of treatment: response rate and complete response rate (CR), progression-free survival (PFS), response duration (RD) and overall survival (OS).

All subjects who received at least one dose of Temsirolimus (Torisel™) will be considered evaluable and will be included in the safety analysis.

Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).

A Multicenter Phase IB Dose Escalation Study to Evaluate the Safety, Feasibility and Efficacy of the Torisel-Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (T-R-CHOP), Torisel-Rituximab-Fludarabine-Cyclophosphamide (T-R-FC) and Torisel-Rituximab-Aracytine High Dose-Dexamethasone (T-R-DHA) for the Treatment of Patients in Relapsed/Refractory Mantle Cell Lymphoma

The evaluable for DLT population is the subset of patients from all treated population with a DLT assessment at the two first cycles.

Response at the end of treatment will be assessed after four cycles and at the end of complete treatment if the patient received all planned cycles or at withdrawal. Patients without response assessments (due to whatever reason) will be considered non-responders. A descriptive analysis will also be performed considering as non-responders all patients who relapsed or died during the treatment phase even if they were prematurely withdrawn as responders.

Progression-Free Survival will be measured from the date of inclusion to the date of first documented disease progression, relapse or death from any cause, according to the Cheson 2007 criteria. Responding patients and patients who are lost to follow up will be censored at their last tumor assessment date.

Duration of response will be measured from the date of first documentation of a response (CR or PR at the end of treatment) to the date of first documented evidence of progression/relapse or death from any cause, according to the Cheson 2007 criteria. Responding patients and patients who are lost to follow up will be censored at their last tumor assessment date.

The same disease response assessment used for complete response rate will be considered to determine the Overall Response Rate. A Patient will be defined as a responder if he/she has a complete response (CR/CRu) or partial response (PR) after four cycles and at the end of treatment. A descriptive analysis will also be performed considering as non-responders all patients who relapsed or died during treatment phase even if they were prematurely withdrawn as responders.

Overall survival will be measured from the date of inclusion to the date of death from any cause. Patients who are alive at the time of analysis will be censored at the date of the last contact.

All subjects who received at least one dose of Temsirolimus (Torisel™) will be considered evaluable and will be included in the safety analysis.

Analysis of safety will be performed by summarizing adverse events, laboratory data, vital signs and ECOG per-formance status. When applicable, a summary of safety data will also be performed by cycle.

French Innovative Leukemia Organisation

The Lymphoma Academic Research Organisation

MB-106, single intravenous infusion up to 3.3 x 10e7 chimeric antigen receptor t-cells (CAR-T cells)/kg

MB-106, single intravenous infusion up to 3.3 x 10e7 CAR-T cells/kg

MB-106, single intravenous infusion. Dose based upon outcome Phase 1.

T-cells derived from autologous leukapheresis that are genetically modified.

MB-106

Premier Research

Harmonie Strohl

Jeremy S. Abramson, M.D.

M. Lia Palomba, MD

Kaitlyn Burrows

Patrick Reagan, MD

Cancer Awareness Department

SCCA Immunotherapy Intake

Mazyar Shadman, MD

Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL

This is a multicenter, Phase 1/2, open-label, non-randomized study of MB-106 in patients ≥18 years of age with selected CD20-expressing malignancies.

In both the Phase 1 and Phase 2 portions of the study, all patients must have evidence of CD20 expression.

In Phase 1, patients will be enrolled in 1 of 3 arms, based on their primary diagnosis, as follows:

* Arm 1: Patients with aggressive B-cell non-Hodgkin lymphoma (NHL) including, but not limited to, diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
* Arm 2: Patients with indolent NHL including, but not limited to, follicular lymphoma (FL).
* Arm 3: Patients with chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL).

In Phase 1, escalating MB-106 dose levels will be tested independently in each arm using a 3+3 design.

A total of up to 18 patients are anticipated to be treated in each independent arm in Phase 1, including 6 patients at the maximum tolerated dose (MTD; highest dose level at which ≤1 of 6 patients experiences a dose-limiting toxicity \[DLT\]), prior to proceeding to the Phase 2 portion of the study for each respective arm, where a total of up to 71 patients will participate in each independent arm.

An assessment of the safety and tolerability of the dose will be made by the Safety Review Committee (SRC) based on the data from the 28-day DLT observation period.

An SRC composed of Principal Investigators and Sponsor representatives will review the safety of each dose level for each arm prior to enrollment at the next dose level in the Phase 1 dose escalation part of study. This process will be repeated for each dose level within each arm until the MTD has been reached, and the recommended Phase 2 dose (RP2D) has been established for that arm.

In Phase 2, the following specific arms of relapsed or refractory CD20-positive B-cell NHL or CLL patients will be treated with MB-106 at the respective RP2D for each arm. Each arm will initially include up to 20 patients:

* Arm 1 Expansion (E): Relapsed or refractory DLBCL, including high-grade B-cell lymphoma with MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements, primary mediastinal large B-cell lymphoma and transformed FL.
* Arm 2E: Relapsed or refractory FL.
* Arm 2E-Basket: Relapsed or refractory B-cell NHL subtypes that have progressed after available therapies. This "basket" arm will include but will not be limited to MCL, marginal zone lymphoma (MZL), Waldenstrom's macroglobulinemia (WMG), Burkitt and Burkitt-like lymphoma, and hairy cell leukemia (HCL).
* Arm 3E: Relapsed or refractory CLL/SLL

Arms 1E, 2E and 3E of Phase 2 will have an interim efficacy analysis for futility prior to completion of recruitment to the arm. Arm 2E-Basket will be summarized descriptively only. Safety data from all arms will also be provided at this interim timepoint to the Data Safety Monitoring Board (DSMB) for review. Based on the results of the interim analysis, an additional 51 patients may be added to each of these arms.

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

A Phase 1/2, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

The safety, tolerability, and feasibility of MB-106 in patients with relapsed or refractory CD20+ B-cell NHL or CLL.

Incidence of treatment-emergent AEs (TEAEs) as assessed by CTCAE v5.0, including serious adverse events (SAEs), therapy-related AEs, Grade 3 or 4 TEAEs, TEAEs with an outcome of death (i.e., Grade 5 TEAEs), and TEAEs leading to study discontinuation.

To determine the RP2D of MB-106 in each of the 3 arms in patients with relapsed or refractory CD20+ B-cell NHL or CLL.

The RP2D will be the highest MB-106 dose in each arm that is associated with fewer than 2 cases of DLT in 6 patients.

To assess the efficacy of MB-106 as measured by objective response rate (ORR) according to the Lugano Classification for Lymphomas for patients with NHL. For patients with CLL, ORR will be assessed according to the 2018 Modified International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute-Working Group. ORR will be determined by the percentage of patients achieving complete remission (CR) or partial remission (PR) as their best response. Radiology scans will be assessed for response by an Independent Central Reviewer.

To assess the efficacy of MB-106 as measured by objective response rate (ORR) according to the Lugano Classification for Lymphomas for patients with NHL. For patients with CLL, ORR will be assessed according to the 2018 Modified International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute-Working Group for patients with CLL. ORR will be determined by percentage of patients achieving complete remission (CR) or partial remission (PR) as their best response.

To assess the efficacy of MB-106, as measured by duration of response (DOR), progression-free survival (PFS), and overall survival (OS).

To assess the total number of patients with minimal residual disease (MRD) in CLL patients.

To assess the safety, tolerability, and feasibility of MB-106 in patients with relapsed or refractory CD20+ B-cell NHL or CLL.

Incidence of treatment-emergent AEs (TEAEs) as assessed by CTCAE v5.0, including serious adverse events (SAEs), therapy-related AEs, Grade 3 or 4 TEAEs, TEAEs with an outcome of death (i.e., Grade 5 TEAEs), and TEAEs leading to study discontinuation.

Total number of patients with minimal residual disease (MRD) in CLL patients.

National Cancer Institute (NCI)

Amino Acids

Venetoclax

Ibrutinib

Navitoclax

Tyrosine Kinase Inhibitors

Tyrosine

Patients without the high-risk mutations (no 9p21.1-24.3 loss, no SMARCA2 or SMARCA4 mut/del) will be treated with ibrutinib, rituximab and venetoclax.

Patients with the high-risk mutations (9p21.1-24.3 loss, SMARCA2 and/or SMARCA4 mut/del) will be treated with ibrutinib, rituximab, venetoclax and navitoclax.

Oral daily. Dose escalation every 7 days (if no TLS) 20mg, 50mg, 100mg, 200mg and 400mg

Oral daily. Dose-escalation every 14 days (if plt \>75x10\^9/L) 50mg, 100mg, 150mg, and 200mg (target dose)

375mg/m2, intravenous. To be given on day 1 of weeks 1, 2, 3, 4 of C1 and day 1 of C2-C8

Mary-Ann Anderson

Paula Marlton

Bryone Kuss

Mary Ann Anderson

This is an open label, multi-centre, phase II study in which RR MCL patients will be genetically risk-stratified into Standard risk (no 9p21.1-24.3 loss, no SMARCA2 or SMARCA4 mut/del) and High risk (9p21.1-24.3 loss, SMARCA2 and/or SMARCA4 mut/del).

Patients without the high-risk mutations will be treated with ibrutinib, rituximab and venetoclax. Patients with the high-risk mutations will be treated with ibrutinib, rituximab, venetoclax and navitoclax.

The combination of ibrutinib and venetoclax in patients with RR MCL (50% TP53 aberrant) was explored in the AIM1 study. It demonstrated a CR rate of 71% (p\<0.001) with an estimated 15 month PFS and 18-month OS of 78% and 74% respectively. Importantly, using ASO-PCR with sensitivity of 1 in 104-105, 56% of all patients and 82% of those who had achieved CR were MRD-negative. The combination was well tolerated with generally low-grade side effects including diarrhoea (83%), fatigue (75%) and nausea or vomiting (71%). Tumour lysis occurred in 8% (n=2) of the cohort. These results led to the initiation of a global phase III registration study comparing ibrutinib vs ibrutinib-venetoclax in patients with RR MCL (ClinicalTrials number NCT03112174).

The addition of anti-CD20 monoclonal antibodies (mAb) has significantly improved the outcomes in indolent and aggressive B-cell lymphomas. For instance, in Australia, the 5-year OS has improved from 53.4% in 1997 to 67.9% in 2007 largely due to incorporation of rituximab into the standard treatment regimens. In a phase II study of patients with RR MCL, the addition of rituximab to ibrutinib resulted in a considerably higher CR rate (44%) than with ibrutinib monotherapy (21%).The combination of an anti-CD20 mAb with a BTK and BCL-2 inhibitor was explored in the OSASIS study which combined obinutuzumab with ibrutinib and venetoclax in RR MCL (n=12). Venetoclax was administered at the dose range of 200-800mg.The combination resulted in high response rates and MRD-negativity in 77% of those who had achieved CR. Toxicities included haematological grade 3-4 AEs (58%), no dose limiting toxicity (DLT) and no clinically significant non-haematological Grade 3-4 AEs. However, it is unknown what the CR rate and MRD-negativity rates are in genetically defined risk groups in this small study.

Despite the encouraging results of AIM1, approximately 30% of patients failed to respond to the ibrutinib and venetoclax combination or relapsed whilst on study therapy after initially achieving CR. Genomic analysis of these patients in comparison to those who had sustained responses identified 9p21.1-24.3 loss or mutations in the SWI/SNF chromatin remodelling complex (SMARCA2 and/or SMARCA4 mut/del) as mechanisms of resistance through transcriptional upregulation of BCL-xL.20 This is a BCL2 family protein not targeted by venetoclax therefore providing a selective advantage against venetoclax-based therapy.

Navitoclax, a BCL2/BCL-XL/BCL-W inhibitor, was demonstrated by our in-vitro data to be able to overcome the resistance in SWI/SNF mutant cells, resensitising them to the ibrutinib-venetoclax combination.The combination of navitoclax and venetoclax has been recently explored in RR acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma. Venetoclax was administered at 200mg on day 1 followed by 400mg daily thereafter. Navitoclax was administered at 3 dose levels (25mg, 50mg and if \>45kg also 100mg). Common non-haematological AEs included diarrhoea (47%), nausea (47%), hypokalaemia (45%) and abdominal pain (43%) while Grade 3-4 haematologic AEs included febrile neutropenia (47%), thrombocytopenia (26%) and anaemia (17%). The incidence of grade 3-4 thrombocytopenia in this study is consistent with existing data on navitoclax toxicity profile. It is caused by navitoclax-mediated inhibition of Bcl-XL leading to accelerated platelet apoptosis. Combination with venetoclax allows for lower doses of navitoclax which can mitigate the effect on platelets.

Although there is no published data on the combination of navitoclax and rituximab, the safety and synergy of rituximab and navitoclax in CLL and indolent lymphoma has been reported with better response rates than in Phase I studies with either agent alone.

The AIM1 study demonstrated ibrutinib and venetoclax to be a highly effective treatment strategy for patients with RR MCL. Ancillary questions that we will address include:

1. Can addition of rituximab to the venetoclax and ibrutinib combination increase the depth and durability of response RR MCL?
2. Can addition of navitoclax in high-risk RR MCL improve rates of CR?
3. What is the safety and tolerability of these combinations?

The rationale for the staggered drug introduction and dose titration:

1. Ibrutinib and rituximab lead-in before venetoclax (and navitoclax in high-risk group):

   * Ibrutinib lead-in is expected to sensitise the lymphoma cells to venetoclax
   * Rituximab-induced rapid cytoreduction in order to reduce the tumour cell numbers and therefore the risk of patients harbouring MCL cells capable of adaption to the BH3-mimetics
   * Maintaining the same dosing schedule of ibrutinib and venetoclax as AIM1 in the standard-risk cohort would allow direct comparison with AIM1
2. Navitoclax dosing:

   * Given the ability of BCL-xL to be rapidly up-regulated in response to venetoclax and ibrutinib, co-administration of navitoclax and venetoclax is crucial. Navitoclax will therefore be introduced in week 4, i.e. after 3 weeks
   * We acknowledge that recovery of the platelet count whilst on navitoclax relies on compensatory mechanisms by the bone marrow, which may be suppressed by venetoclax, however, in order to effectively inhibit BCL-XL, we propose a target dose of 200mg with careful up-titration from an initial dose of 50mg as guided by the platelet count
   * Furthermore, recovery of navitoclax-induced thrombocytopenia would partially depend on the bone marrow reserve. Bone marrow involvement in MCL has been reported in 5029-63%30 of cases which is significantly lower than in CLL or ALL. We therefore anticipate that the impact of navitoclax on platelet count would be better compensated in MCL than in diseases with greater degree of bone marrow infiltration. Importantly, only 2 out of 24 patients (8%) on AIM1 study had a platelet count of \<75 x 109/L at screening. Throughout the first 16 weeks, the platelet count remained \>75 x 109/L in 92% and \>50 x 109/L in 96% of patients (unpublished data)
   * Additionally, in order to mitigate the risk of ibrutinib-related bleeding exacerbated by Grade 3-4 thrombocytopenia, ibrutinib and navitoclax will be withheld until platelet count is ≥25 x 109/L and there is no further bleeding.

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

A Phase II Study of Genetically Risk-Stratified Combination of Venetoclax, Ibrutinib and Rituximab (With and Without Navitoclax) in Patients With Relapsed and Refractory Mantle Cell Lymphoma (AIM2)

Standard risk MCL (no 9p21.1-24.3 loss, SMARCA2 or SMARCA4 mut/del): to evaluate the depth of response to venetoclax and ibrutinib in combination with rituximab in the treatment of patients with MCL, as determined by MRD clearance rate at 16 weeks.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.	NCT05645744	Blastic Plasmac... Chronic Lymphoc... Small Lymphocyt... Waldenstrom's M... Follicular B-ce... B-cell Lymphoma... Mantle Cell Lym... Hairy Cell Leuk... Diffuse Large B... Waldenstrom's M... Mantle Cell Lym...	Prior MB-102 CA... Prior MB-106 CA...	18 Years -	Mustang Bio
Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).	NCT01389427	Mantle Cell Lym...	Torisel dose 15... Torisel dose 15... Torisel dose 15... Torisel dose 25... Torisel dose 50... Torisel dose 75... Torisel dose 25... Torisel dose 50... Torisel dose 75... Torisel dose 25... Torisel dose 50... Torisel 75 mg a...	18 Years -	The Lymphoma Academic Research Organisation
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL	NCT05360238	Follicular B-ce... Mantle Cell Lym... Mantle Cell Lym... Small Lymphocyt... Waldenstrom's M... Waldenstrom's M... Chronic Lymphoi... B-cell Lymphoma...	MB-106	18 Years -	Mustang Bio
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL	NCT05360238	Follicular B-ce... Mantle Cell Lym... Mantle Cell Lym... Small Lymphocyt... Waldenstrom's M... Waldenstrom's M... Chronic Lymphoi... B-cell Lymphoma...	MB-106	18 Years -	Mustang Bio
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.	NCT05645744	Blastic Plasmac... Chronic Lymphoc... Small Lymphocyt... Waldenstrom's M... Follicular B-ce... B-cell Lymphoma... Mantle Cell Lym... Hairy Cell Leuk... Diffuse Large B... Waldenstrom's M... Mantle Cell Lym...	Prior MB-102 CA... Prior MB-106 CA...	18 Years -	Mustang Bio
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL	NCT05360238	Follicular B-ce... Mantle Cell Lym... Mantle Cell Lym... Small Lymphocyt... Waldenstrom's M... Waldenstrom's M... Chronic Lymphoi... B-cell Lymphoma...	MB-106	18 Years -	Mustang Bio
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma	NCT05864742	Mantle Cell Lym...	Ibrutinib Venetoclax Navitoclax Rituximab	18 Years -	Peter MacCallum Cancer Centre, Australia

Spots Global Cancer Trial Database for mantle cell lymphoma refractory